OPKO Guides Q3 Revenue to $131M-$142M, Topping Q2's $163.5M
OPK sits 47% above its 52-week low of $0.977.
Summary
OPKO Health issued Q3 revenue guidance of $131M-$142M, a sequential decline from Q2's $163.5M but a notable improvement over Q1's $124.2M. The midpoint of $136.5M suggests stabilization after a 17% YoY drop in Q1. This follows the Q2 8-K filed earlier today showing a dramatically narrowed net loss of $8.4M. The guidance provides the first official look into the second half, giving traders a concrete range to model against consensus. With shares at $1.44 and a sub-$1B market cap, any revenue trajectory shift is material.
At the time of this announcement, OPK was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.3M. The 52-week trading range was $0.98 to $1.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.